[1]
|
Xu, J., Shen, C., Wang, T., et al. (2013) Structural Basis for the Inhibition of Polo-Like Kinase 1. Nature Structural & Molecular Biology, 20, 1047-1053. https://doi.org/10.1038/nsmb.2623
|
[2]
|
Kettenbach, A.N., Schweppe, D.K., Faherty, B.K., et al. (2011) Quantitative Phosphoproteomics Identifies Substrates and Functional Modules of Aurora and Polo-Like Kinase Activities in Mitotic Cells. Science Signaling, 4, rs5.
https://doi.org/10.1126/scisignal.2001497
|
[3]
|
Bai, Y., Li, J., Fang, B., et al. (2012) Phosphoproteomics Identifies Driver Tyrosine Kinases in Sarcoma Cell Lines and Tumors. Cancer Research, 72, 2501-2511. https://doi.org/10.1158/0008-5472.CAN-11-3015
|
[4]
|
Bieging, K.T., Mello, S.S. and Attardi, L.D. (2014) Un-ravelling Mechanisms of p53-Mediated Tumour Suppression. Nature Reviews Cancer, 14, 359-370. https://doi.org/10.1038/nrc3711
|
[5]
|
Salvi, M., Trashi, E., Cozza, G., et al. (2012) Investigation on PLK2 and PLK3 Substrate Recognition. Biochimica et Biophysica Acta, 1824, 1366-1373.
|
[6]
|
Bruinsma, W., Macurek, L., Freire, R., et al. (2014) Bora and Aurora-A Continue to Activate Plk1 in Mitosis. Journal of Cell Science, 127, 801-811. https://doi.org/10.1242/jcs.137216
|
[7]
|
Craig, S.N., Wyatt, M.D. and McInnes, C. (2014) Current Assessment of Polo-Like Kinases as Anti-Tumor Drug Targets. Expert Opinion on Drug Discovery, 9, 773-789. https://doi.org/10.1517/17460441.2014.918100
|
[8]
|
Gjertsen, B.T. and Schoffski, P. (2015) Discovery and Development of the Polo-Like Kinase Inhibitor Volasertib in Cancer Therapy. Leukemia, 29, 11-19. https://doi.org/10.1038/leu.2014.222
|
[9]
|
Cholewa, B.D., Liu, X. and Ahmad, N. (2013) The Role of Polo-Like Kinase 1 in Carcinogenesis: Cause or Consequence? Cancer Research, 73, 6848-6855. https://doi.org/10.1158/0008-5472.CAN-13-2197
|
[10]
|
McInnes, C. and Wyatt, M.D. (2011) PLK1 as an Oncology Target: Current Status and Future Potential. Drug Discovery Today, 16, 619-625.
|